Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) — Market Cap & Net Worth
Market Cap & Net Worth: Eyepoint Pharmaceuticals Inc (EYPT)
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) has a market capitalization of $285.62 Million ($285.62 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15143 globally and #3577 in its home market, demonstrating a -24.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eyepoint Pharmaceuticals Inc's stock price $3.45 by its total outstanding shares 82787220 (82.79 Million). Also see EYPT total assets for a full breakdown of the balance sheet.
Eyepoint Pharmaceuticals Inc Market Cap History: 2015 to 2026
Eyepoint Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $3.99 Billion to $285.62 Million (-19.99% CAGR). Also see Eyepoint Pharmaceuticals Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Eyepoint Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #415 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1469 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.02% | #212 of 263 |
Weight: Eyepoint Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Eyepoint Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eyepoint Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check EYPT stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
14.25x
Eyepoint Pharmaceuticals Inc's market cap is 14.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.99 Billion | $26.57 Million | $6.35 Million | 150.21x | 628.70x |
| 2016 | $1.42 Billion | $1.62 Million | -$21.55 Million | 873.87x | N/A |
| 2017 | $894.10 Million | $7.54 Million | -$18.48 Million | 118.60x | N/A |
| 2018 | $1.56 Billion | $2.96 Million | -$53.17 Million | 528.43x | N/A |
| 2019 | $1.28 Billion | $20.36 Million | -$56.79 Million | 63.01x | N/A |
| 2020 | $544.74 Million | $34.44 Million | -$45.39 Million | 15.82x | N/A |
| 2021 | $1.01 Billion | $36.94 Million | -$58.42 Million | 27.43x | N/A |
| 2022 | $289.76 Million | $41.40 Million | -$102.25 Million | 7.00x | N/A |
| 2023 | $1.91 Billion | $46.02 Million | -$70.80 Million | 41.58x | N/A |
| 2024 | $616.76 Million | $43.27 Million | -$130.87 Million | 14.25x | N/A |
Competitor Companies of EYPT by Market Capitalization
Companies near Eyepoint Pharmaceuticals Inc in the global market cap rankings as of September 17, 2026. Review EYPT goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Eyepoint Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Eyepoint Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Eyepoint Pharmaceuticals Inc's market cap moved from $3.99 Billion to $ 285.62 Million, with a yearly change of -19.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $285.62 Million | -81.12% |
| 2025 | $1.51 Billion | +145.23% |
| 2024 | $616.76 Million | -67.76% |
| 2023 | $1.91 Billion | +560.29% |
| 2022 | $289.76 Million | -71.41% |
| 2021 | $1.01 Billion | +86.02% |
| 2020 | $544.74 Million | -57.55% |
| 2019 | $1.28 Billion | -17.99% |
| 2018 | $1.56 Billion | +75.00% |
| 2017 | $894.10 Million | -36.84% |
| 2016 | $1.42 Billion | -64.52% |
| 2015 | $3.99 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Eyepoint Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $285.62 Million USD |
| MoneyControl | $285.62 Million USD |
| MarketWatch | $285.62 Million USD |
| marketcap.company | $285.62 Million USD |
| Reuters | $285.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib… Read more